Cogent Biosciences reports Q2 2026 results, two bezuclastinib PDUFA dates aheadAug 10Quarterly updatebezuclastinibCogent Biosciences, Inc.
Cogent Biosciences files $400 million stock offering under existing at-the-market programAug 10FinancingbezuclastinibCogent Biosciences, Inc.
GSK posts bepirovirsen QT results; registers Mo-Rez ovarian, endometrial Phase 3 trialsJul 10Weekly roundup, 6 itemsbepirovirsencamlipixant
Sign inSign in